2. Activity Goals

3. Case Presentation

4. Rai Staging

5. Prognostic Markers

6. Multivariate Cox Proportional Hazards Model for Survival (n = 1617)

7. Risk Categories

8. Diagnostic Tests

9. MDACC Data: Time to First Treatment

10. Initial Treatment Choices

11. PFS in Patients > 70 y: Across Treatment Regimens

12. Effect of Comorbidity on Outcome of Initial Therapy

13. Bendamustine  Rituximab

14. Actuarial PFS With Single-Agent Rituximab

15. Chlorambucil + Rituximab

16. Novel Agents

17. Ibrutinib (PCI-3276)

18. Idelalisib + Rituximab

19. Supportive Care

20. Forthcoming Trial Data

21. Conclusions About Older Patients With CLL

22. Abbreviations

23. Abbreviations (cont)

24. References

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)